Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Dyadic International, Inc. is a global biotechnology company based in Jupiter, Flo...
Dyadic International, Inc. is a global biotechn...
Trevena is a biopharmaceutical company focused on the development and commercializ...
Trevena is a biopharmaceutical company focused ...
Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...
Scopus BioPharma develops small molecule therap...
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...
Immunomedics is a clinical-stage biopharmaceuti...
We are a clinical-stage specialty pharmaceutical company dedicated to the developm...
We are a clinical-stage specialty pharmaceutica...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
Join the National Investor Network and get the latest information with your interests in mind.